MeTA: Overview and lessons learned in pilot countriesMeTApresents
Presentation on MeTA, overview and lessons learned in pilot countries by MeTA's Executive Director, during the World Health Assembly (WHA), Geneva on19 May 2009.
Presentation on Concept and structure of MeTA by Wilbert Bannenberg, MeTA Technical Director during the MeTA Country Sharing Meeting, London, 8 December 2009.
Medicines Transparency Alliance (MeTA) : country progress and key lessonsMeTApresents
This presentation shares the progress to date of the pilot phase of the Medicines Transparency Alliance (MeTA) and was given by Wilbert Banneberg, Technical Director of the International MeTA Secretariat at the launch of MeTA Jordan in May 2009
MeTA: Overview and lessons learned in pilot countriesMeTApresents
Presentation on MeTA, overview and lessons learned in pilot countries by MeTA's Executive Director, during the World Health Assembly (WHA), Geneva on19 May 2009.
Presentation on Concept and structure of MeTA by Wilbert Bannenberg, MeTA Technical Director during the MeTA Country Sharing Meeting, London, 8 December 2009.
Medicines Transparency Alliance (MeTA) : country progress and key lessonsMeTApresents
This presentation shares the progress to date of the pilot phase of the Medicines Transparency Alliance (MeTA) and was given by Wilbert Banneberg, Technical Director of the International MeTA Secretariat at the launch of MeTA Jordan in May 2009
Webinar 2: Matching Access to Risk
When: May 27, 2021 @ 1:00pm – 2:30pm EST
Toon Digneffe, Head EU Public Affairs & Public Policy, Takeda Slides. Early Access & RWE: building trust and reducing
stakeholder uncertainties – a European perspective
Matching Access to Risk, but Who Pays? Who decides how much risk to accept with a new medicine? How does each stakeholder make that decision? The developer balances availability and ROI. The regulatory makes a population benefit-risk calculation. The clinician compares an unknown drug with known benefits-risks. The payer introduces a third trade-off, cost. And the patient who literally has the most at risk often has the least say.
A panel will deliberate on ways to introduce, manage, and sustain access to medicines that are matched to the types and levels of “risk?” When should managed access programs be used, or not? When do you need bigger, longer, broader clinic trials, and when should we rely on “real-world” data? How can genomic profiling target individuals with highly precise medications? How can blockchain technology and artificial intelligence be used to improve treatment algorithms and cost-effective use?
A presentation given by Dr Joanna Raven of the PERFORM2Scale consortium and Liverpool School of Tropical Medicine. Entitled 'How do you effectively facilitate health systems interventions?' the presentation was given at the Sept 2019 European Congress on Tropical Medicine and International Health.
Tracking Family Planning Spending Using the System of Health Accounts FrameworkHFG Project
Karishmah Bhuwanee traveled to Bali, Indonesia in January 2016 to attend and present at the International Conference on Family Planning at the request of the USAID Office on Population and Reproductive Health. This presentation helped promote USAID’s global leadership on the topics of results based financing in family planning supply chains, family planning inclusion in universal health coverage initiatives and the importance of resource tracking to improve family planning programming.
Tracking Family Planning Spending Using the System of Health Accounts FrameworkHFG Project
Karishmah Bhuwanee traveled to Bali, Indonesia in January 2016 to attend and present at the International Conference on Family Planning at the request of the USAID Office on Population and Reproductive Health. This presentation helped promote USAID’s global leadership on the topics of results based financing in family planning supply chains, family planning inclusion in universal health coverage initiatives and the importance of resource tracking to improve family planning programming.
Sets out the five core principles which guide the operation of the Medicines Transparency Alliance (MeTA) in efforts to increase transparency, accountability and governance around the supply of essential medicines.
Introductory perspectives -- Andrew Blazey & Chris James, OECDOECD Governance
This presentation was made by Andrew Blazey & Chris James, OECD, at the Health Systems Joint Network Meeting for Central, Eastern and South-Eastern European Countries, held in Tallinn, Lithuania, on 25-26 April 2019
This presentation was given by Samantha Reddin at a research communications capacity building workshop at the Institute of Development Studies in April 2008.
Webinar 2: Matching Access to Risk
When: May 27, 2021 @ 1:00pm – 2:30pm EST
Toon Digneffe, Head EU Public Affairs & Public Policy, Takeda Slides. Early Access & RWE: building trust and reducing
stakeholder uncertainties – a European perspective
Matching Access to Risk, but Who Pays? Who decides how much risk to accept with a new medicine? How does each stakeholder make that decision? The developer balances availability and ROI. The regulatory makes a population benefit-risk calculation. The clinician compares an unknown drug with known benefits-risks. The payer introduces a third trade-off, cost. And the patient who literally has the most at risk often has the least say.
A panel will deliberate on ways to introduce, manage, and sustain access to medicines that are matched to the types and levels of “risk?” When should managed access programs be used, or not? When do you need bigger, longer, broader clinic trials, and when should we rely on “real-world” data? How can genomic profiling target individuals with highly precise medications? How can blockchain technology and artificial intelligence be used to improve treatment algorithms and cost-effective use?
A presentation given by Dr Joanna Raven of the PERFORM2Scale consortium and Liverpool School of Tropical Medicine. Entitled 'How do you effectively facilitate health systems interventions?' the presentation was given at the Sept 2019 European Congress on Tropical Medicine and International Health.
Tracking Family Planning Spending Using the System of Health Accounts FrameworkHFG Project
Karishmah Bhuwanee traveled to Bali, Indonesia in January 2016 to attend and present at the International Conference on Family Planning at the request of the USAID Office on Population and Reproductive Health. This presentation helped promote USAID’s global leadership on the topics of results based financing in family planning supply chains, family planning inclusion in universal health coverage initiatives and the importance of resource tracking to improve family planning programming.
Tracking Family Planning Spending Using the System of Health Accounts FrameworkHFG Project
Karishmah Bhuwanee traveled to Bali, Indonesia in January 2016 to attend and present at the International Conference on Family Planning at the request of the USAID Office on Population and Reproductive Health. This presentation helped promote USAID’s global leadership on the topics of results based financing in family planning supply chains, family planning inclusion in universal health coverage initiatives and the importance of resource tracking to improve family planning programming.
Sets out the five core principles which guide the operation of the Medicines Transparency Alliance (MeTA) in efforts to increase transparency, accountability and governance around the supply of essential medicines.
Introductory perspectives -- Andrew Blazey & Chris James, OECDOECD Governance
This presentation was made by Andrew Blazey & Chris James, OECD, at the Health Systems Joint Network Meeting for Central, Eastern and South-Eastern European Countries, held in Tallinn, Lithuania, on 25-26 April 2019
This presentation was given by Samantha Reddin at a research communications capacity building workshop at the Institute of Development Studies in April 2008.
MeTA: Overview and lessons learned in pilot countriesMeTApresents
Presentation on MeTA overview and lessons learned in pilot countries by Brian Elliot, Executive Director, MeTA, during the World Health Assembly (WHA), Geneva on 19 May 2009.
MRC/info4africa KZN Community Forum | October 2012info4africa
Kwazi Mbatha, a CEGAA Researcher/Trainer for the BMET project,was joined by a member of TAC’s uMgungundlovu District community mobilisation team to discuss challenges and opportunities for HIV/AIDS and TB budget monitoring at local levels in South Africa. Relating primarily to CEGAA’s Budget Monitoring and Expenditure (BMET) project, conducted in partnership with the Treatment Action Campaign and entitled "Giving power to the community: Community monitoring of HIV/AIDS and TB spending in two districts in South Africa", this project worked towards increasing the delivery, accessibility, affordability and quality of treatment for people living with HIV/AIDS and TB, thus ensuring that ARVs and TB treatments are available as life-saving and prevention mechanisms. The pilot and secondary phase of the project sought to achieve the above by empowering communities and citizens towards a common understanding of health care delivery and budget issues and collaborative corrective action for optimal health care services at local level.
A quoi sert la recherche sur les politiques et les systèmes de santé? Point d...valéry ridde
Par Denis Porignon.
Plénière d'ouverture du Colloque Post-Vancouver 2016, sur la recherche francophone sur les politiques et systèmes de santé dans les pays à faible et moyen revenu, organisé par la Chaire REALISME, à l’IRSPUM, Montréal, le 21 novembre 2016.
MeTA pilot countries support needs and recommendationsMeTApresents
An overview of MeTA pilot countries support needs and recommendations, a presentation by Elodie Brandamir, MeTA Operations Director during the MeTA countries sharing meeting, London 2009
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.